Market Place
Sourcing Support
Tempest Extends Limited Duration Stockholder Rights Plan
10 Oct 2024 //
GLOBENEWSWIRE
Tempest And Roche Agreement to Amezalpat For Hepatocellular Carcinoma
10 Oct 2024 //
GLOBENEWSWIRE
Tempest Reports Inducement Grants Under Nasdaq Rule
20 Sep 2024 //
GLOBENEWSWIRE
Tempest Appoints Sheldon Mullins As VP Regulatory Affairs
18 Sep 2024 //
GLOBENEWSWIRE
Tempest To Present At H.C. Wainwright Investment Conference
05 Sep 2024 //
GLOBENEWSWIRE
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23 Aug 2024 //
GLOBENEWSWIRE
Tempest Appoints Troy Wagner As VP Of Quality Assurance
21 Aug 2024 //
GLOBENEWSWIRE
Tempest Successfully Completes End-of-Phase 2 Meeting For Amezalpat
15 Aug 2024 //
GLOBENEWSWIRE
Tempest Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Tempest Unveils New Data For Amezalpat Showing Six-Month Improvement
20 Jun 2024 //
GLOBENEWSWIRE
Tempest to Report New Data of Amezalpat in First-Line Hepatocellular Carcinoma
18 Jun 2024 //
GLOBENEWSWIRE
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
GLOBENEWSWIRE
Tempest to Participate in Upcoming Investor Conferences
21 May 2024 //
GLOBENEWSWIRE
Tempest Reports Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26 Apr 2024 //
GLOBENEWSWIRE
Tempest Reports Data for TPST-1120 in RCC at the AACR Annual Meeting
09 Apr 2024 //
GLOBENEWSWIRE
Tempest Announces Publication of Data from Ph 1 Trial of TPST-1120 in Journal
04 Apr 2024 //
GLOBENEWSWIRE
Tempest Reports Year End 2023 Financial Results and Provides Business Update
19 Mar 2024 //
GLOBENEWSWIRE
Tempest Presents New Data at the SITC 2024
12 Mar 2024 //
GLOBENEWSWIRE
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120
05 Mar 2024 //
GLOBENEWSWIRE
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
26 Feb 2024 //
GLOBENEWSWIRE
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
GLOBENEWSWIRE
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Jan 2024 //
GLOBENEWSWIRE
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2023 //
GLOBENEWSWIRE
Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
20 Nov 2023 //
GLOBENEWSWIRE
Tempest Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Tempest soars on new data for TPST-1120 in first-line liver cancer
12 Oct 2023 //
YAHOO FINANCE
Tempest Releases New Data Demonstrating Superiority of TPST-1120
11 Oct 2023 //
GLOBENEWSWIRE
Tempest Adopts Limited Duration Stockholder Rights Plan
11 Oct 2023 //
GLOBENEWSWIRE
Tempest to Report Data from Randomized Combination Study of TPST-1120
10 Oct 2023 //
GLOBENEWSWIRE
Tempest Announces Expanded Role for Sam Whiting as CMO
19 Sep 2023 //
GLOBENEWSWIRE
Tempest to Present at H.C. Wainwright 25th Annual Global Investment Conference
05 Sep 2023 //
GLOBENEWSWIRE
Tempest Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495
19 Jul 2023 //
GLOBENEWSWIRE
Tempest to Present at the Jefferies Global Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Tempest to Present Phase 1 Monotherapy & Combination Data at ASCO for TPST-1495
25 May 2023 //
GLOBENEWSWIRE
G Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
19 May 2023 //
GLOBENEWSWIRE
Tempest Reports 1Q 2023 Financial Results and Provides Business Update
10 May 2023 //
GLOBENEWSWIRE
Tempest’s triple combo shows promise in first-line liver cancer, stock jumps
28 Apr 2023 //
ENDPTS
Tempest to Report Early Results Ph 1b/2 Combination Study of TPST-1120
27 Apr 2023 //
GLOBENEWSWIRE
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
26 Apr 2023 //
GLOBENEWSWIRE
Tempest Announces New Translational and Preclinical Dataat the 2023 AACR
17 Apr 2023 //
GLOBENEWSWIRE
Tempest Reports Year End 2022 Financial Results and Provides Business Update
22 Mar 2023 //
GLOBENEWSWIRE
Tempest to Present Biomarker Data for TPST-1120 at SITC
15 Mar 2023 //
GLOBENEWSWIRE
Tempest to Present New Preclinical Data at the 2023 AACR Annual Meeting
14 Mar 2023 //
GLOBENEWSWIRE
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
GLOBENEWSWIRE
Tempest Reports3Q 2022 Financial Results and Provides Business Update
08 Nov 2022 //
GLOBENEWSWIRE
Tempest to Present at the H.C. Wainwright 24th Annual GIC
07 Sep 2022 //
GLOBENEWSWIRE
Tempest Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Tempest to Participate in Panel Discussion at 2022 William Blair Conference
07 Jul 2022 //
GLOBENEWSWIRE
Tempest Provides ASCO KOL Feedback on TPST-1120 Results
09 Jun 2022 //
GLOBENEWSWIRE
Tempest to Present at the Jefferies Healthcare Conference
06 Jun 2022 //
GLOBENEWSWIRE
Tempest Reports Positive TPST-1120 Clinical Data from PI Trial in Solid Tumors
26 May 2022 //
GLOBENEWSWIRE
Tempest Reports First Quarter 2022 Financial Results
13 May 2022 //
GLOBENEWSWIRE
Tempest Announces Private Placement Financing of $15 Million
27 Apr 2022 //
GLOBENEWSWIRE
Tempest Announces Oral and Poster Presentations at Upcoming 2022 ASCO
27 Apr 2022 //
GLOBENEWSWIRE
Tempest Presents Promising Preclinical Data on Two Oncology Programs at AACR
08 Apr 2022 //
GLOBENEWSWIRE
Tempest Reports Year End 2021 Financial Results and Provides Business Update
29 Mar 2022 //
GLOBENEWSWIRE
Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference
10 Mar 2022 //
GLOBENEWSWIRE
Tempest to Present Two Posters at the 2022 AACR
08 Mar 2022 //
GLOBENEWSWIRE
